Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. - Rediti M; Fernandez-Martinez A; Venet D; Rothé F; Hoadley KA; Parker JS; Singh B; Campbell JD; Ballman KV; Hillman DW; Winer EP; El-Abed S; et al. (Nature communications, 2023)